Cancer Biology Commons^™

Use Of Checkpoint Inhibitors In Gray Zone Lymphoma, Yensy Mariana Zelaya Rosales, Juliene Lima Mesquita, Yhasmine Delles Oliveira Garcia, Fernando Ricardo Fernandes Paz, Naiana Castelo Branco Campos, Joa˜O Paulo De Vasconcelos Leita˜O, Francisco Da´Rio Rocha Filho, Ricardo Vale Albino Oliveira Filho, Rome´Lia Pinheiro Gonc¸Alves Lemes, Fernando Barroso Duarte

Hematology/Oncology and Stem Cell Therapy

Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. This is a case report of a difficult diagnosis and describes the most current treatment using checkpoint inhibitors, through the review of the clinical record of a patient diagnosed with gray area …